Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457332 | 1.00 | NPSR1 (0.36) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL29457333 | 1.00 | NPSR1 (0.36) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL21174014 | 0.88 | KEAP1 (0.33) | MAPTATMTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL29457327 | 0.87 | KEAP1 (0.46) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL7172244 | 0.87 | KEAP1 (0.46) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL4458375 | 0.87 | KEAP1 (0.46) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL29733883 | 0.87 | KEAP1 (0.46) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL7012803 | 0.87 | KEAP1 (0.46) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL2083262 | 0.82 | MEN1 (0.39) | NPSR1MEN1KMT2AMAPTGAA | |
| SCHEMBL2083261 | 0.82 | MEN1 (0.39) | NPSR1MEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376100-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. | 2024-11-14 | — | — | US | disclosed |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| EP-4114831-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Twentyeight-Seven, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-115554294-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115477649-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115429798-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-109689656-B | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | NPSR1 1072/4885MEN1 3502/4885KMT2A 2845/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | NPSR1 1072/4885MEN1 3502/4885KMT2A 2845/4885 |
| US-20240376100-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | PAPSS1, OTUD7B, BRD7 | NPSR1 2922/4885MEN1 3213/4885KMT2A 2390/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | NPSR1 3301/4885MEN1 2158/4885KMT2A 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.